Major health plans and PBMs have built institutional knowledge of how to structure formulary decisions, step therapy requirements, and prior authorization criteria to accelerate biosimilar adoption and have financial incentives to deploy that knowledge more aggressively than in the adalimumab cycle
The oxidation of 2-deoxy-8-oxoguanosine by iodine
10.1016/j.ejbas.2018.06.001 52 EnginS.BarutE
Here's the honest picture: it's based on a real, powerful body chemical, it's not approved for the way people use it, and it carries genuine risks that make it different from the 'gentler' peptides
Theres very little direct negotiation compared to other parts of the world, and the result is that patients pay the price. Acting as middlemen, PBMs negotiate drug prices on behalf of insurance companies and have been accused of prioritizing their profits over patient access
But it does highlight why combining medication with long-term strategies like balanced nutrition, regular exercise, and behavior changes is essential